Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three and six months ended June 30, 2013, and provided an update on the Company's upcoming merger with Immune Pharmaceuticals, Ltd. (Immune).

Robert Cook, Interim President and CEO of EpiCept, commented, "Our excitement about the merger between EpiCept and Immune is growing as we get closer to the stockholder vote on August 6 and to the closing of the merger transaction shortly after obtaining stockholder approval. We believe the combination of our companies will benefit both sets of shareholders and will in particular provide EpiCept's stockholders with a great opportunity to participate in the antibody therapeutics sector, one of the most dynamic in the biotech industry. We look forward to our transition into a new company, Immune Pharmaceuticals, Inc, focused on these cutting-edge products."

Mr. Cook added, "We are very pleased with the results of the vote to date with more than 93% of the votes cast so far in favor of the proposals.  We fully anticipate that our Special Meeting of Stockholders on August 6 will result in our meeting the final conditions to the closing of this important transaction."

Merger UpdateIn November 2012, following the approval of the companies' respective boards of directors, EpiCept signed a merger agreement with Immune Pharmaceuticals Ltd., a private company based in Herzliya-Pituach, Israel and New York, NY. The terms of the merger agreement provide that, upon the closing of the transaction, EpiCept will issue shares of its common stock to Immune shareholders in exchange for all outstanding shares of Immune and issue options and warrants to purchase shares of its common stock in exchange for certain options and warrants to purchase shares of Immune.  EpiCept stockholders will own approximately 19% of the combined company and Imm
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... LEXINGTON, Mass., March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 28th Annual Health Care Conference, ... conference is being held in,Boston, Massachusetts. The presentation will ... the Investors section of the Indevus website at, http://www.indevus.com ...
... March 11 Scott Lett, CEO of The,BioAnalytics ... make,scientific presentations at the Tucson Symposium on March ... Drug Discovery,Development and Clinical Diagnostics," will be attended ... biotechnology and,medical device industries., Dr. Lett,s invited ...
... STRASBOURG, France, March 11 Transgene,(Euronext Paris: FR0005175080) ... 2007 and outlook for 2008., "2007 was ... major,accomplishments: the signing of a partnership agreement with ... treatment of diseases caused by the,HPV virus, and ...
Cached Biology Technology:Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 3Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 4Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 5Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 6Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 7Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 8Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 9Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 10Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 11Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 12
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Worker bees 'know' when to invest in their reproductive future 2
... 2011 Qqest and M2SYS Technology, a global biometrics ... allows Qqest to offer TimeForce time and attendance customers ... technology at their PC. M2SYS, RightPunch(TM) solution ... to seamlessly interface with Qqest,s TimeForce time and attendance ...
... In communities all across the US, travelers that went to the ... their quiet lives. The voyagers in question are not astronauts. ... moon trees orbited the moon 34 times in the Apollo 14 ... the lunar module landed at Fra Mauro, Earth peeks over the ...
... Trees growing on farms will be essential to future development. ... year, the number of trees on farms is increasing. Marking ... United Nations Forum on Forests (UNFF9) in New York on ... Agroforestry Centre, highlighted the importance of mixing trees with agriculture, ...
Cached Biology News:Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3A race against time to find Apollo 14's lost voyagers 2A race against time to find Apollo 14's lost voyagers 3A race against time to find Apollo 14's lost voyagers 4Putting trees on farms fundamental to future agricultural development 2Putting trees on farms fundamental to future agricultural development 3Putting trees on farms fundamental to future agricultural development 4
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Viruses microRNA Microarray contains all known ...
... At the forefront of Agilent analytical solutions ... local area networking (LAN) allows you to ... fast and informed decision making. Just as ... all the flexibility and performance needed for ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: